Viewing data from:

HALOPERIDOL DECANOATE

ANDA

HALOPERIDOL DECANOATE | A074811 | HIKMA PHARMACEUTICALS USA INC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Haloperidol Decanoate (2023)

Total Spending

$16.7M

Total Claims

304,271

Beneficiaries

34,910

Avg Cost/Unit

$32.35

Spending Trend

$15.9M(2019)→$16.8M(2020)→$17.7M(2021)→$17.8M(2022)→$16.7M(2023)

YoY Change:-6.8%

5yr CAGR:-3.3%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain5 active DMFs2 inactive

5 active API suppliers hold Drug Master Files for this ingredient.

JANSSEN PHARMACEUTICA NVHALOPERIDOL DECANOATE

DMF 109541994

TAPI NL BVHALOPERIDOL DECANOATE

DMF 125301997

OLON SPAHALOPERIDOL DECANOATE

DMF 169492003

MSN LIFE SCIENCES PRIVATE LTDHALOPERIDOL DECANOATE USP

DMF 337032019

MANKIND PHARMA LTDHALOPERIDOL DECANOATE USP

DMF 343532020

PFC ITALIANA SRL DIV ALFA CHEMICALS ITALIANAInactiveHALOPERIDOL DECANOATE

DMF 66821986

EXCELLA GMBHInactiveHALOPERIDOL DECANOATE

DMF 191972006

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — EQ 50MG BASE/ML

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Jan 30, 1998

No patent or exclusivity listings for this strength.